Experts Discuss Personalized ctDNA Assays to Predict Immunotherapy Response.

Citation metadata

Date: Sept. 2021
From: Oncology(Vol. 35, Issue 9)
Publisher: Intellisphere, LLC
Document Type: Clinical report
Length: 1,043 words
Lexile Measure: 1450L

Document controls

Main content

Article Preview :

Despite the broad success of immunotherapy across different solid tumor and hematologic malignancies, reliable biomarkers of response to immune checkpoint blockade have eluded investigators, creating an unmet medical need in the oncology space.

The recently reported prospective phase 2 INSPIRE study (NCT02644369) aimed to address this need by examining circulating tumor DNA (ctDNA) in 5 distinct cohorts of patients with advanced solid tumors using bespoke assays.

In a recent Between the Lines discussion, George Ansstas, MD, reviewed key findings from the trial with Firas B. Badin, MD, with a focus on the benefit of this study and the personalization of therapy selection.

Regarding the results of this strategy for predicting therapy response, Ansstas, who is an associate professor of medicine at Washington University School of Medicine in St Louis, Missouri, said, "It's the best biomarker we currently have to predict [which patients have a] durable response and longevity."

"'Personalized' is important to highlight here. There are many different assays that simply look at [ctDNA], or fragments of cancer cells in the blood," Badin, who is a medical oncologist with the Baptist Health Medical Group in Lexington, Kentucky, explained. "Here we are using a personalized assay by using tissue as well as patient's blood. That really guides our approach to reliably evaluate response [and may] correlate with survival."

INSPIRE Design and Results

In total, 106 patients with metastatic or advanced solid tumors were enrolled in the study, with 94 (89%) having sufficient tumor tissue for exome sequencing analysis. The 5 parallel cohorts included patients with head and neck squamous cell carcinoma...

Source Citation

Source Citation   

Gale Document Number: GALE|A679525843